Letrasan 2.5

ACTIVE HALF-LIFE 2 days
CLASSIFICATION Non-steroidal aromatase inhibitor
DOSAGE 0.5 - 2.5 mg/day
ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Deva
WAREHOUSE International Warehouse 2
SUBSTANCE Letrozole ,

Letrasan, produced by Deva, is an anti-estrogen medication that is widely used in both medical and athletic contexts. In healthcare, it is mainly used to treat estrogen-related cancers, such as breast cancer in women. In sports, its primary role is to counteract the negative effects of estrogenic steroids, which can range from water retention to gynecomastia in men, among other issues.

This drug is classified as a non-steroidal aromatase inhibitor with Letrozole as its active ingredient. It has been approved for human use, is not a steroid, lacks androgenic effects, is not particularly toxic, does not harm the liver, and is free from narcotic or addictive properties.

When ingested, Letrasan acts as an aromatase inhibitor, controlling an enzyme responsible for estrogen production. It works by inhibiting the cytochrome P450 enzyme complex within aromatase. Prolonged use of the drug can lead to a reduction of estrogen activity by 75-95% compared to initial levels.

Letrasan is part of the third generation of aromatase inhibitors. Anastrozole is a similar, but not identical, compound, whereas Clomid and Nolvadex function as estrogen receptor blockers. These alternatives differ in their mechanisms of action and final outcomes since they do not reduce estrogen production but only interfere with estrogen's binding to its receptors.

It is noteworthy that Letrasan is considered relatively safe when used according to guidelines, with minimal side effects for most individuals. However, those predisposed to certain conditions or who misuse the medication may experience gastrointestinal issues (like nausea and dry mouth), central nervous system effects (such as dizziness and depression), respiratory problems (ranging from shortness of breath to coughing), and musculoskeletal issues (including joint pain and osteoporosis). In cases of overdose, symptomatic treatment is typically administered.

Letrasan should be taken orally, with or without food, as it is rapidly and completely absorbed in the gastrointestinal tract with a bioavailability of 99%. Food does not significantly affect its action.

The recommended dosage ranges from 0.25 to 2.5 mg daily, depending on individual needs and tolerance. The drug can be used in two primary ways: 1) as a preventive measure against the complications of estrogenic steroids, or 2) as an adjunct during a steroid cycle to manage estrogen-related issues once they arise. Either approach effectively helps prevent estrogen-related side effects like water retention, increased body fat, and gynecomastia in men.

Prior to starting Letrasan, it is essential to evaluate potential risks. Consulting a healthcare professional is recommended to rule out contraindications, such as pregnancy, breastfeeding, and specific endocrine issues in women. Both men and women should be cautious if they have sensitivities to any of the drug's components or if they are underage.

Certain conditions warrant careful use of Letrasan, including glucose-galactose malabsorption and lactose intolerance, which could lead to adverse effects. Generally, this medication does not require dose adjustments.

Keep out of reach of children. Intended for adult use only.